Last updated: November 10, 2023
Sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Overall Status: Terminated
Phase
3
Condition
Rett Syndrome
Autism
Seizure Disorders (Pediatric)
Treatment
ZX008 (Fenfluramine Hydrochloride)
Clinical Study ID
NCT03299842
ZX008-1503-SS01
Ages 2-35 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Meeting all of the main study ZX008-1503 [NCT02823145] inclusion criteria
- Subject is willing to wear the Embrace watch on the wrist (alternatively ankle, ifneeded for younger children). Subjects are asked to wear the watch for as many hoursof the day as possible and for the entire night, if possible, for the duration of thesub-study.
- Subject's parent/caregiver is willing to use the Alert App.
- Subject/subject's caregiver is willing to ensure that the Embrace watch remains withinclose proximity of the paired iPod Touch running the Empatica Alert app.
Exclusion
Exclusion Criteria:
- Subject has a known hypersensitivity to any of the Embrace device materials.
- Subject has a clinically significant condition, or has had clinically relevantsymptoms or a clinically significant illness in the 4 weeks prior to Visit 1, otherthan epilepsy, that would negatively impact study participation, collection of studydata, or pose a risk to the subject.
Study Design
Total Participants: 5
Treatment Group(s): 1
Primary Treatment: ZX008 (Fenfluramine Hydrochloride)
Phase: 3
Study Start date:
July 12, 2017
Estimated Completion Date:
July 05, 2018
Study Description
Connect with a study center
University of California San Francisco
San Francisco, California 94143
United StatesSite Not Available
The Children's Hospital Colorado
Aurora, Colorado 80045
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.